Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients

Angus, 2000, Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: Can we meet the requirements of an aging population?, JAMA, 284, 2762, 10.1001/jama.284.21.2762 Marik, 2006, Management of the critically ill geriatric patient, Crit Care Med, 34, S176, 10.1097/01.CCM.0000232624.14883.9A Heffner, 2000, A wake-up call in the intensive care unit, N Engl J Med, 342, 1520, 10.1056/NEJM200005183422011 Kollef, 1998, The use of continuous iv sedation is associated with prolongation of mechanical ventilation, Chest, 114, 541, 10.1378/chest.114.2.541 Kress, 2000, Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation, N Engl J Med, 342, 1471, 10.1056/NEJM200005183422002 MacIntyre, 2001, Evidence-based guidelines tbr weaning and discontinuing ventilatory support: A collective task force facilitated by the American College of Chest Physicians, the American Association for Respiratory Care, and the American College of Critical Care Medicine, Chest, 120, 375S, 10.1378/chest.120.6_suppl.375S Marquis, 2000, Neuropsychological sequelae in survivors of ARDS compared with critically ill control patients {abstract], Am J Respir Crit Care Med, 161, A383 Rothenhausler, 2001, The relationship between cognitive performance and employment and health status in long-term survivors of the acute respiratory distress syndrome: Results of an exploratory study, Gen Hosp Psychiatry, 23, 90, 10.1016/S0163-8343(01)00123-2 Hopkins, 1999, Neuro-psychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome, Am J Respir Crit Care Med, 160, 50, 10.1164/ajrccm.160.1.9708059 Jackson, 2003, Six-month neuro-psychological outcome of medical intensive care unit patients, Crit Care Med, 31, 1226, 10.1097/01.CCM.0000059996.30263.94 Sukantarat, 2004, Dysexecutive syndrome after critical illness [abstract], Am J Respir Crit Care Med, 169, A628 Al-Saidi, 2003, Neuro-psychological sequelae in ARDS survivors [abstract], Am J Respir Crit Care Med, 167, A737 Moller, 1998, Long-term postoperative cognitive dysfunction in the elderly ISPOCDI study, Lancet, 351, 857, 10.1016/S0140-6736(97)07382-0 Marcantonio, 1994, The relationship of postoperative delirium with psychoactive medications, JAMA, 272, 1518, 10.1001/jama.1994.03520190064036 Francis, 1990, A prospective study of delirium in hospitalized elderly, JAMA, 263, 1097, 10.1001/jama.1990.03440080075027 Ely, 2004, Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit, JAMA, 291, 1753, 10.1001/jama.291.14.1753 Pandharipande, 2006, Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients, Anesthesiology, 104, 21, 10.1097/00000542-200601000-00005 Ely, 2003, Monitoring sedation status over time in ICU patients: Reliability and validity of the Richmond Agitation-Sedation Scale (RASS), JAMA, 289, 2983, 10.1001/jama.289.22.2983 Greenblatt, 2000, Kinetics and dynamics of lorazepam during and after continuous intravenous infusion, Crit Care Med, 28, 2750, 10.1097/00003246-200008000-00011 Dershwitz, 2000, Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers, Anesthesiology, 93, 619, 10.1097/00000542-200009000-00009 Uerpairojkit, 2003, A randomized controlled study of three targets of propofol plasma concentration in patients undergoing uterine dilation and curettage, J Obstet Gynaecol Res, 29, 79, 10.1046/j.1341-8076.2003.00083.x Frenkel, 1995, Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients, Intensive Care Med, 21, 981, 10.1007/BF01700659 Malacrida, 1992, Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients, Crit Care Med, 20, 1123, 10.1097/00003246-199208000-00010 Barr, 2001, A double-blind, randomized comparison of iv lorazepam versus midazolain for sedation of ICU patients via a pharmacologic model, Anesthesiology, 95, 286, 10.1097/00000542-200108000-00007 Barr, 2001, Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model, Anesthesiology, 95, 324, 10.1097/00000542-200108000-00011 Jacobi, 2002, Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult, Crit Care Med, 30, 119, 10.1097/00003246-200201000-00020 Peng, 1999, A review of the use of fentanyl analgesia in the management of acute pain in adults, Anesthesiology, 90, 576, 10.1097/00000542-199902000-00034 Sessler, 2002, The Richmond Agitation-Sedation Scale: Validity and reliability in adult intensive care unit patients, Am J Respir Crit Care Med, 166, 1338, 10.1164/rccm.2107138 Knaus, 1985, APACHE II: A severity of disease classification system, Crit Care Med, 13, 818, 10.1097/00003246-198510000-00009 Gunawan, 1988, Determination of lorazepam in plasma of patients during status epilepticus by high-performance liquid chromatography, Ther Drug Monit, 10, 172, 10.1097/00007691-198802000-00010 Plummer, 1987, Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection, J Chromatogr, 421, 171, 10.1016/0378-4347(87)80394-8 Shibutani, 2005, Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients, Br J Anaesth, 95, 377, 10.1093/bja/aei195 Ely, 2001, The impact of delirium in the intensive care unit on hospital length of stay, Intensive Care Med, 27, 1892, 10.1007/s00134-001-1132-2 Esteban, 2002, Characteristics and outcomes in adult patients receiving mechanical ventilation: A 28-day international study, JAMA, 287, 345, 10.1001/jama.287.3.345 Greenblatt, 1991, Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I), Clin Pharmacokinet, 21, 165, 10.2165/00003088-199121030-00002 Greenblatt, 1991, Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II), Clin Pharmacokinet, 21, 262, 10.2165/00003088-199121040-00003 Renton, 2001, Alteration of drug biotransformation and elimination during infection and inflammation, Pharmacol Ther, 92, 147, 10.1016/S0163-7258(01)00165-6 Chung, 2005, Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers, Clin Pharmacol Ther, 77, 486, 10.1016/j.clpt.2005.02.006 Young, 2000, Sedation in the intensive care unit, Crit Care Med, 28, 854, 10.1097/00003246-200003000-00041 Barr, 1995, Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit, Crit Care Clin, 11, 827, 10.1016/S0749-0704(18)30041-1 Casati, 2005, Anesthesia in the obese patient: Pharmacokinetic considerations, J Clin Anesth, 17, 134, 10.1016/j.jclinane.2004.01.009 Kieffer, 2002, Opioid tolerance—in search of the holy grail, Cell, 108, 587, 10.1016/S0092-8674(02)00666-9 Dominguez, 2006, Withdrawal from lorazepam in critically ill children, Ann Pharmacother, 40, 1035, 10.1345/aph.1G701 Kyrklund, 2000, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin Pharmacol Ther, 68, 592, 10.1067/mcp.2000.111414 McCune, 2000, In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone, Clin Pharmacol Ther, 68, 356, 10.1067/mcp.2000.110215 Pascussi, 2000, Dexamethasone induces pregnane X receptor and retinoid X receptor- alpha expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators, Mol Pharmacol, 58, 361, 10.1124/mol.58.2.361 Villikka, 2001, Effect of methyl- prednisolone on CYP3A4-mediated drug metabolism in vivo, Eur J Clin Pharmacol, 57, 457, 10.1007/s002280100340 Ahonen, 1999, Interaction between fluconazole and midazolam in intensive care patients, Acta Anaesthesiol Scand, 43, 509, 10.1034/j.1399-6576.1999.430504.x Pinto, 2005, Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein, BrJ Clin Pharmacol, 59, 440, 10.1111/j.1365-2125.2005.02343.x